Coluracetam

Drug Profile

Coluracetam

Alternative Names: BCI-540; MKC-231

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Chemical
  • Developer BrainCells; Mitsubishi Chemical; Takeda
  • Class Neuroprotectants; Nootropics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Anxiety disorders; Major depressive disorder

Most Recent Events

  • 26 Jun 2012 Coluracetam is available for licensing as of 26 Jun 2012. http://www.braincellsinc.com
  • 15 May 2012 Mitsubishe Tanabe Pharma terminates a licence agreement for coluracetam (Mitsubishi Tanabe Pharma May 8 2012 pipeline)
  • 16 Jun 2010 Safety and efficacy data from a phase IIa trial in Major depressive disorder with anxiety released by BrainCells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top